Healthcare -
Biotechnology - NASDAQ - US
$ 2.83
0 %
$ 169 M
Market Cap
-3.77
P/E
1. INTRINSIC VALUE
Balance Sheet
Eledon Pharmaceuticals, Inc.
| Current Assets | 144 M |
| Cash & Short-Term Investments | 140 M |
| Receivables | 0 |
| Other Current Assets | 3.55 M |
| Non-Current Assets | 33.7 M |
| Long-Term Investments | 0 |
| PP&E | 926 K |
| Other Non-Current Assets | 32.7 M |
| Current Liabilities | 11.6 M |
| Accounts Payable | 5.83 M |
| Short-Term Debt | 314 K |
| Other Current Liabilities | 5.43 M |
| Non-Current Liabilities | 47.7 M |
| Long-Term Debt | 640 K |
| Other Non-Current Liabilities | 47 M |
EFFICIENCY
Earnings Waterfall
Eledon Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 70.6 M |
| Operating Income | 0 |
| Other Expenses | 36.2 M |
| Net Income | -36.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Eledon Pharmaceuticals, Inc.
| Net Income | -36.2 M |
| Depreciation & Amortization | 359 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 13.1 M |
| Change in Working Capital | 8.71 M |
| Others | -32.8 M |
| Free Cash Flow | -47.3 M |
Wall Street Analysts Price Targets
Eledon Pharmaceuticals, Inc.
ELDN has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ELDN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Eledon Pharmaceuticals, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
4.75 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
4.58 M USD 1
9-12 MONTHS
7. News
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2024 operating and financial results and reviewed recent business highlights.
globenewswire.com
- 1 month ago
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
globenewswire.com
- 1 month ago
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
globenewswire.com
- 2 months ago
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
globenewswire.com
- 2 months ago
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment.
seekingalpha.com
- 2 months ago
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Completed two financings totaling $135 million in combined gross proceeds, with funds expected to support operations through end of 2026 IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2024 accomplishments and provided guidance for anticipated 2025 business milestones.
globenewswire.com
- 3 months ago
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Announced oversubscribed $85 million underwritten offering, with proceeds expected to extend cash runway to the end of 2026 IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2024 operating and financial results and reviewed recent business highlights.
globenewswire.com
- 5 months ago
Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart
Positive phase 1b biomarker and eGFR data achieved from phase 1b study using tegoprubart for prevention of organ rejection in kidney transplant patients. Top-line data from the phase 2 BESTOW study, using tegoprubart for prevention of organ rejection in kidney transplant patients, expected in Q4 of 2025. The organ transplant immunosuppressant drugs market is expected to reach $6.4 billion by 2030.
seekingalpha.com
- 5 months ago
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant.
globenewswire.com
- 5 months ago
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based immunosuppression - Treatment with tegoprubart was generally well tolerated - Study data to be presented by UChicago Medicine's team in oral presentation at the 5 th IPITA/HSCI/Breakthrough T1D Stem Cells Summit IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the Company's investigational anti-CD40L antibody, for prevention of islet transplant rejection in subjects with type 1 diabetes (T1D).
globenewswire.com
- 5 months ago
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C.
globenewswire.com
- 7 months ago
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants
globenewswire.com
- 7 months ago
8. Profile
Summary
Eledon Pharmaceuticals, Inc. ELDN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 169 M
Dividend Yield
0.00%
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Contact
19900 MacArthur Boulevard, Irvine, CA, 92612
https://eledon.com
IPO
Date
Sept. 17, 2014
Employees
31
Officers
Dr. Steven N. Perrin Ph.D.
President, Chief Scientific Officer & Non Independent Director
Mr. Bryan E. Smith J.D.
General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. David Hovland Ph.D.
Chief Regulatory Officer
Dr. Eliezer Katz F.A.C.S., FACS, M.D.
Chief Medical Officer
Mr. John Herberger
Vice President of Technical Operations
Ms. Marina Escudero
Vice President & Head of Clinical Operations
Dr. David-Alexandre C. Gros M.D., Ph.D.
Chief Executive Officer & Non Independent Director
Mr. Paul Sean Little
Chief Financial Officer